Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Patent
1978-02-01
1980-01-15
Rosen, Sam
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
424 94, 424358, A61K 4700, A61K 3748
Patent
active
041839609
ABSTRACT:
The present invention relates to liquid membrane capsules which rupture when contacted with biliary or pancreatic secretions in the intestine thereby releasing their contents in the intestine so the contents become fully available for the treatment of disease at that location in the animal or patient. Particularly, the rupturable liquid membrane capsules containing urease are used for the treatment of chronic uremia. The liquid membrane capsules comprise an internal aqueous phase which contains an oil insoluble medicinal of choice, some complexing agent, dietary supplement or enzyme particularly suited for the intended treatment. This internal aqueous and oil insoluble phase is encapsulated in a nonaqueous external phase comprising a biologically inert oil component, and a material which will complex with the biliary and/or pancreatic secretions in the intestine thereby causing the rupture of the external phase resulting in the release of the internal phase in the intestine. Thus, the internal phase is isolated during passage through the mouth, esophagus, and stomach. On the absence of this isolation the material might be an irritant or be degraded in some of these areas.
The invention is further related to a method of in vivo detoxification comprising the use of liquid membrane capsules containing detoxification materials such as medicinals and/or enzymes as an aqueous internal phase encapsulated in a continuous external phase comprising an oil which external phase further contains an additive which complexes with the biliary and/or pancreatic secretions in the intestine causing the rupture of the external phase, the detoxification process proceeding by the rupture of the external phase resulting in the release of the internal phase in the intestine. The internal phase in this case is such that it will bring about a conversion of certain toxins in the intestine to forms that can readily be trapped by conventional toxin trapping LMC as described by prior art.
REFERENCES:
patent: 3932657 (1976-01-01), Rahman
Gregoriadis-FEBS Letters, vol. 36, No. 3 (Nov. 1973), pp. 292-296.
Asher William J.
Vogler Tina C.
Allocca Joseph J.
Exxon Research & Engineering Co.
Rosen Sam
LandOfFree
Detoxification by means of the controlled, in vivo secretion tri does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detoxification by means of the controlled, in vivo secretion tri, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detoxification by means of the controlled, in vivo secretion tri will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1028552